Edition:
United States

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

103.43USD
4:00pm EDT
Change (% chg)

$1.32 (+1.29%)
Prev Close
$102.11
Open
$104.39
Day's High
$104.54
Day's Low
$103.12
Volume
44,330
Avg. Vol
34,723
52-wk High
$121.08
52-wk Low
$72.92

Select another date:
Photo

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

BRIEF-Galapagos Presents Strong Disease-Modifying Effects With Glpg1972 At Oarsi 2018

* REG-GALAPAGOS PRESENTS STRONG DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODEL OF OSTEOARTHRITIS WITH GLPG1972 AT OARSI 2018

BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros

* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO

BRIEF-Galapagos NV Q1 Basic And Diluted Loss Per Share EUR 0.73

* GALAPAGOS EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018

BRIEF-Galapagos NV Creates New Warrant Plan

* BOARD OF DIRECTORS CREATED 1.6 MILLION WARRANTS UNDER NEW WARRANT PLANS

BRIEF-Galapagos Announces ISABELA Phase 3 Program In IPF

* ANNOUNCES THE DESIGN OF A WORLDWIDE PHASE 3 PROGRAM, TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

BRIEF-Galapagos Announces Isabela Phase 3 Program In IPF

* ANNOUNCES DESIGN OF A WORLDWIDE PHASE 3 PROGRAM TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

Select another date: